federalnoe gosudarstvennoe byudzhetnoe uchrezhdenie "Natsionalnyj issledovatelskij tsentr epidemiologii i mikrobiologii imeni pochetnogo akademika N.F. Gamalei" Ministerstva zdravookhraneniya Rossijsk
发明人:
Zubkova Olga Vadimovna (RU),Зубкова Ольга Вадимовна (RU),Ozharovskaya Tatyana Andreevna (RU),Ожаровская Татьяна Андреевна (RU),Dolzhikova Inna Vadimovna (RU),Должикова Инна Вадимовна (RU),Popova Olga
申请号：
RU2018131949
公开号：
RU0002709659C1
申请日:
2018.09.06
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology, immunology and virology. Described is an immunobiological agent based on human recombinant adenovirus 5-th serotype or recombinant human adenovirus 26-th serotype, containing optimized expression in mammal cells consensus sequence of complete protective antigen S of MERS virus on the basis of sequences of protein S genes of modern strains of virus MERS 2015–2017 years with sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5. Method for using the immunobiological agent for inducing specific immunity to MERS-CoV. Method of using the immunobiological agent consists in the sequential introduction into the body of mammals of two different immunobiological agents based on human recombinant adenovirus of 5-th serotype or two different immunobiological agents based on human recombinant adenovirus of 26-th serotype with a period of more than 1 week, for inducing specific immunity to MERS-CoV. There is also developed a method for using the immunobiological agent consisting in consecutive introduction into an organism of mammals of any of the immunobiological agents based on human recombinant adenovirus of 5-th serotype and any of the immunobiological preparations based on human recombinant adenovirus 26-th serotype with a period of more than 1 week, for the induction of specific immunity to MERS-CoV, or in consecutive introduction into organism of mammals of any of immunobiological agents on the basis of recombinant human adenovirus of 26-th serotype and any of immunobiological agents on the basis of recombinant human adenovirus of 5-th serotype with interval of more than 1 week, for induction of specific immunity to MERS-CoV. There is also developed a method for using an immunobiological agent consisting in simultaneous introduction into an organism of mammals of any two immunobiological agents on the basis of recombinant human adenovirus of 5-th serotype for induction of specific
